Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | SVP, Chief Medical Officer | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUPERNUS PHARMACEUTICALS, INC.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,342 |
Reported balance
After 2026-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-12 · Exercise / conversion · Acquired 750 · Balance 14,342 F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 13,979 |
Reported balance
After 2026-08-12 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-12 · Tax withholding · Disposed 363 · Balance 13,979 F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. |
| Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-12 · Exercise / conversion · Disposed 750 · Balance 0 F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2024 Filed Feb 26, 2024 22:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027581 · tm247055-12_4seq1.xml · derivative · entry 3 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 750 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. F4 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 303 | $27.94 | $8,465.82 |
DisclosureSEC source: 0001104659-24-027581 · tm247055-12_4seq1.xml · nonDerivative · entry 2 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,958 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027581 · tm247055-12_4seq1.xml · nonDerivative · entry 1 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,261 F1 · balance_after: Includes an aggregate of 268 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-129243 · tm2333640-2_4seq1.xml · derivative · entry 3 Rubin Jonathan · CIK 0001836067 · Sr. VP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2022. F3 · derivative.exercise_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. F3 · derivative.expiration_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 204 | $27.66 | $5,642.64 |
DisclosureSEC source: 0001104659-23-129243 · tm2333640-2_4seq1.xml · nonDerivative · entry 2 Rubin Jonathan · CIK 0001836067 · Sr. VP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,243 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-129243 · tm2333640-2_4seq1.xml · nonDerivative · entry 1 Rubin Jonathan · CIK 0001836067 · Sr. VP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2022. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-126930 · tm2333121-1_4seq2.xml · derivative · entry 2 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 600 shares Expires not disclosed F2 · derivative.exercise_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. F2 · derivative.expiration_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-026088 · tm237737-20_4seq1.xml · derivative · entry 3 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 23, 2024. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 23, 2024. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-23-026088 · tm237737-20_4seq1.xml · derivative · entry 2 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 23, 2024. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025366 · tm237737-6_4seq1.xml · derivative · entry 2 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025366 · tm237737-6_4seq1.xml · nonDerivative · entry 1 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,497 F1 · balance_after: Includes an aggregate of 247 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-023832 · tm237193-2_4seq1.xml · derivative · entry 2 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2031-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On April 30 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-023832 · tm237193-2_4seq1.xml · nonDerivative · entry 1 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on April 30, 2021. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004285 · tm233672-1_4seq1.xml · derivative · entry 1 Rubin Jonathan · CIK 0001836067 · Sr. VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2031-04-30 F1 · derivative.exercise_date: On April 30 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026877 · tm227622-10_4seq1.xml · derivative · entry 2 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001104659-22-026877 · tm227622-10_4seq1.xml · derivative · entry 1 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 22:15 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-027392 · tm227764-2_4aseq1.xml · derivative · entry 2 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: The Reporting Person is amending Form 4 filed on February 24, 2022 to reflect that these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023, rather than such vesting occurring entirely on February 22, 2023. F3 · derivative.expiration_date: The Reporting Person is amending Form 4 filed on February 24, 2022 to reflect that these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023, rather than such vesting occurring entirely on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 22:15 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001104659-22-027392 · tm227764-2_4aseq1.xml · derivative · entry 1 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2023. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:54 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001104659-21-026939 · tm217706-10_4seq1.xml · derivative · entry 1 Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-02-19 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 19, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.